{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:22:53Z","timestamp":1792106573115,"version":"4.4.0"},"reference-count":37,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>Background:\u00a0Biktarvy is approved for use in HIV-1 infection in both treatment-na\u00efve and treatment-experienced individuals, after a series of successful phase III trials. However, studies on real-world evidence on its efficacy, safety and tolerability are limited. Purpose:\u00a0The study aims to collate real-world evidence on the use of Biktarvy in clinical practice to identify gaps in knowledge. Research Design:\u00a0Scoping review was undertaken using PRISMA guidelines and a systematic search strategy. The final search strategy used was (Bictegravir* OR biktarvy) AND (efficac* OR safe* OR effect* OR tolerab* OR \u2018side effect*\u2019 OR \u2018adverse effect*\u2019). The last search was performed on the 12th of August 2021. Study Sample:\u00a0Studies were eligible if they reported on the efficacy, effectiveness, safety or tolerability of bictegravir-based ART. Data Collection and\/or Analysis:\u00a0Data were collected from 17 studies that met the inclusion and exclusion criteria and summarised using a narrative synthesis. Results:\u00a0The efficacy of Biktarvy in clinical practice is comparable to phase III trials. However, adverse effects and discontinuation rates were found to be higher in real-world studies. Conclusions:\u00a0The cohorts in the included real-world studies showed more demographic diversity when compared to the drug approval trials, further prospective studies are required on under-represented groups such as women, pregnant people, ethnic minorities and older adults.<\/jats:p>","DOI":"10.1177\/13596535231159030","type":"journal-article","created":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T12:24:31Z","timestamp":1676723071000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review"],"prefix":"10.1177","volume":"28","author":[{"given":"Ellen","family":"Peters","sequence":"first","affiliation":[{"name":"Brighton and Sussex Medical School, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-1717","authenticated-orcid":false,"given":"and Collins","family":"Iwuji","sequence":"additional","affiliation":[{"name":"Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton, UK"},{"name":"Africa Health Research Institute, KwaZulu-Natal, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,2,18]]},"reference":[{"key":"bibr1-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01379-9"},{"key":"bibr2-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106343"},{"key":"bibr3-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.8431"},{"key":"bibr4-13596535231159030","unstructured":"European AIDS Clinical Society Guidelines. Available online: https:\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html (accessed on 01\/07\/22)."},{"key":"bibr5-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30077-3"},{"key":"bibr6-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"bibr7-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1010-7"},{"key":"bibr8-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000468"},{"key":"bibr9-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2246"},{"key":"bibr10-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"bibr11-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3018(18)30091-2"},{"key":"bibr12-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32340-1"},{"key":"bibr13-13596535231159030","unstructured":"Hill A, McCann K, Pilkington V, et al. Conference abstract: risks of metabolic syndrome diabetes, and cardiovascular disease in advance, 2020."},{"key":"bibr14-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002731"},{"key":"bibr15-13596535231159030","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"bibr16-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2011.10.001"},{"key":"bibr17-13596535231159030","unstructured":"Jain P, Morrisette T, Scherrer S, et al. Pharmacist-led patient satisfaction survey for people living with human immunodeficiency virus taking single-tablet bictegravir\/emtricitabine\/tenofovir alafenamide after being switched from twotablet dolutegravir plus emtricitabine\/tenofovir alafenamide. In: Proceedings of the 2019 ACCP Annual Meeting, New York, 26-29 October 2019."},{"key":"bibr18-13596535231159030","unstructured":"Tiraboschi J, Prieto P, Saumoy M, et al. Neuropsychiatric, clinical and laboratory changes in patients prospectively switching from elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide to bictegravir\/emtricitabine\/tenofovir alafenamide. In: Proceedings of the HIV Glasgow 2020, Glasgow, 5-8 October 2020."},{"key":"bibr19-13596535231159030","unstructured":"Proud E, Murphy C. Real-world experience using bictegravir\/emtricitabine\/tenofovir-alafenamide (B\/F\/TAF) in a Scottish HIV cohort. In: Proceedings of the HIV Glasgow 2020, Glasgow, 5-8 October 2020."},{"key":"bibr20-13596535231159030","unstructured":"Umland T, Stellbrink H, Calvo M, et al. The clinical relevance of potential drug-drug interactions with bictegravir\/emtricitabine\/tenofovir alafenamide real-world data from the German IQVIA prescription database. In Proceedings the HIV Glasgow 2020, Glasgow, 5-8 October 2020."},{"key":"bibr21-13596535231159030","unstructured":"Rojas Lievano J, Inciarte A, De La Mora L, et al. Experience from a real-life cohort: Outcome of 984 HIV infected patients treated with bictegravir\/emtricitabine\/tenofovir alafenamide in Hospital Clinic, Barcelona. In: Proceedings of the HIV Glasgow 2020, Glasgow, 5-8 October 2020."},{"key":"bibr22-13596535231159030","unstructured":"Lowman E, Lee N, Unger N, et al. Associations with weight change and patient-reported outcomes after switching from efavirenz\/emtricitabine\/tenofovir disoproxil fumarate (EFV\/FTC\/TDF) to bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF). In: Proceedings the HIV Glasgow 2020, Glasgow, 5-8 October 2020."},{"key":"bibr23-13596535231159030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/hiv.12860","volume":"21","author":"Doyle C","year":"2020","journal-title":"HIV Med"},{"key":"bibr24-13596535231159030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/hiv.12860","volume":"21","author":"Clark F","year":"2020","journal-title":"HIV Med"},{"key":"bibr25-13596535231159030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/hiv.12860","volume":"21","author":"Clark F","year":"2020","journal-title":"HIV Med"},{"key":"bibr26-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1189"},{"key":"bibr27-13596535231159030","first-page":"A44","volume":"28","author":"Gutierrez Lorenzo M","year":"2021","journal-title":"Eur J Hosp Pharm"},{"key":"bibr28-13596535231159030","doi-asserted-by":"publisher","DOI":"10.3851\/imp3351"},{"key":"bibr29-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa285"},{"key":"bibr30-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1198"},{"key":"bibr31-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa625"},{"key":"bibr32-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2020.0219"},{"key":"bibr33-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002556"},{"key":"bibr34-13596535231159030","unstructured":"BIKTARVY\u00ae | Safety & Tolerability Information. Available online: https:\/\/www.biktarvyhcp.com\/safety-tolerability\/treatment-naive#efficacy (accessed on 01\/07\/2022)."},{"key":"bibr35-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1999.00694.x"},{"key":"bibr36-13596535231159030","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211073321"},{"key":"bibr37-13596535231159030","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new-guidelines (accessed on 21\/01\/2023)."}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535231159030","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535231159030","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535231159030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:09Z","timestamp":1777380789000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13596535231159030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1177\/13596535231159030"],"URL":"https:\/\/doi.org\/10.1177\/13596535231159030","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"article-number":"13596535231159030"}}